Pauline Dufresne Email

VP, People . X4 Pharmaceuticals

Current Roles

Employees:
148
Revenue:
$16.4M
About
The company is developing two unique programs: our drug candidate, X4P-001, has clinical experience in over 70 subjects and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC). Our second program, X4P-002, is a unique series of late lead molecules that penetrate the blood brain barrier. We will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program. The target, CXCR4, plays a central role in tumor progression enabling cancer cells to establish a favorable microenvironment for growth, particularly in the setting of recurrence. Antagonism of the CXCR4 receptor has demonstrated an ability to inhibit the \"pro-tumor microenvironment\" by unmasking the tumor to the immune system, allowing it to recognize and destroy cancer cells and by eliminating the formation of the tumor blood supply. References:
X4 Pharmaceuticals Address
61 North Beacon Street
Boston, MA
United States
X4 Pharmaceuticals Email

Past Companies

X4 PharmaceuticalsVice President, People
Novartis Institutes for BioMedical Research (NIBR)Global HR Business Partner, Director
Novartis Institutes for BioMedical Research (NIBR)Human Resources Business Partner

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.